Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.7 GBX | +4.58% | +3.79% | +51.38% |
May. 01 | Poolbeg Pharma Secures Full Patent in US for Immunomodulator II | MT |
May. 01 | Poolbeg Pharma celebrates full patent approval for Immunomodulator II | AN |
Business Summary
Number of employees: 12
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 21-04-30 | |
Ian O'Connell
DFI | Director of Finance/CFO | 37 | 20-12-31 |
Carol Dalton
IRC | Investor Relations Contact | - | 20-12-31 |
Bruno Speder
LAW | General Counsel | - | 22-06-30 |
John McEvoy
LAW | General Counsel | 37 | Dec. 31 |
David Allmond
PRN | Corporate Officer/Principal | 54 | Nov. 30 |
Ross Crockett
AUD | Comptroller/Controller/Auditor | - | 21-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Luke O'Neill
BRD | Director/Board Member | 60 | - |
Chief Executive Officer | 53 | 21-04-30 | |
Cathal Friel
FOU | Founder | 59 | 20-08-31 |
Brendan Buckley
BRD | Director/Board Member | 73 | 23-05-23 |
Ian O'Connell
DFI | Director of Finance/CFO | 37 | 20-12-31 |
Eddie Gibson
BRD | Director/Board Member | 50 | 21-06-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 500,000,000 | 386,685,149 ( 77.34 %) | 0 | 77.34 % |
Company contact information
Poolbeg Pharma Plc
Queen Mary BioEnterprises Innovation Centre
E1 2AX, London
+
http://www.poolbegpharma.comSector
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+51.38% | 83.46M | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- POLB Stock
- Company Poolbeg Pharma PLC